A practical reference on Melanotan II: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-14 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Uranium tailings are waste by-product materials left over from the rough processing of uranium-bearing ore. They are not significantly radioactive. Mill tailings are sometimes referred to as 11(e)2 wastes, from the section of the US Atomic Energy Act of 1946 that defines them. Uranium mill tailings typically also contain chemically hazardous heavy metal such as lead and arsenic. Vast mounds of uranium mill tailings are left at many old mining sites, especially in Colorado, New Mexico, and Utah. Although mill tailings are not very radioactive, they have long half-lives. Mill tailings often contain radium, thorium and trace amounts of uranium.
=== Research === G-CSF when given early after exposure to radiation may improve white blood cell counts, and is stockpiled for use in radiation incidents. Mesoblast planned in 2004 to use G-CSF to treat heart degeneration by injecting it into the blood-stream, plus SDF (stromal cell-derived factor) directly to the heart. G-CSF has been shown to reduce inflammation, reduce amyloid beta burden, and reverse cognitive impairment in a mouse model of Alzheimer's disease. Due to its neuroprotective properties, G-CSF is currently under investigation for cerebral ischemia in a clinical phase IIb and several clinical pilot studies are published for other neurological disease such as amyotrophic lateral sclerosis A combination of human G-CSF and cord blood cells has been shown to reduce impairment from chronic traumatic brain injury in rats.
11 January 1919: The Germans recapture Sarnowa and win in Battle of Zbąszyń; Polish victory in Battle of Szubin and capture Łabiszyn, Złotniki and Żnin. 12 January 1919: fighting near Leszno and Lipno. 13 January 1919: The Germans recapture Szamocin. 14 January 1919: The Commission of the NRL appeals to Roman Dmowski for help negotiate a ceasefire. 15 January 1919: failed attempt to recapture Szamocin by Poles. 16 January 1919 The first number of Tygodnik Urzędowy Naczelnej Rady Ludowej, with the laws of the NRL, is published. The Polish government of Ignacy Paderewski has two politicians of Greater Poland: Józef Englich, the minister of treasury, and Kazimierz Hącia, the minister of industry and trade. 17 January 1919: Men born in 1897, 1898, and 1899 are called up and drafted into Great Polish Army. 20 January 1919: the transfer of money to banks of Germany on the other side of the front line is forbidden. 21 January 1919 NRL creates oath of soldiers of Great Polish Army. 22 January 1919 Northern front: Poles are forced to leave Potulice. Southern front: Poles win the Battle of Robaczysko. Joseph Noulens is nominated by Supreme Council of Allied Countries as chief of Allied mission in Poland. 23 January 1919: Poles defend Miejska Górka after heavy fighting. 25 January 1919 Poles capture Babimost and Kargowa. All communication between Greater Poland and Germany is broken. Decree cancels Prussian prohibition of Polish language in schools.
Sources: en.wikipedia.org
==== Roots ==== The word root is developed to include a vowel sound following the term to add a smoothing action to the sound of the word when applying a suffix. The result is the formation of a new term with a vowel attached (word root + vowel) called a combining form. In English, the most common vowel used in the formation of the combining form is the letter -o-, added to the word root. For example, if there is an inflammation of the stomach and intestines, this would be written as gastro- and enter- plus -itis, gastroenteritis. The formation of plurals should usually be done using the rules of the source language. Greek and Latin each have differing rules to be applied when forming the plural form of the word root.
==== Europe ==== In 2008, the European Monitoring Centre for Drugs and Drug Addiction noted that although there were some reports of tablets being sold for as little as €1, most countries in Europe then reported typical retail prices in the range of €3 to €9 per tablet, typically containing 25–65 mg of MDMA. By 2014 the EMCDDA reported that the range was more usually between €5 and €10 per tablet, typically containing 57–102 mg of MDMA, although MDMA in powder form was becoming more common.
=== Writing === Garland began writing Dredd during post-production of his other writing credit Sunshine, and completed his first draft while serving as an executive producer during filming of 28 Weeks Later. Garland's draft revolved around one of Dredd's main enemies, the undead Judge Death. He described the story as a "riff on the whole Judge system", but that it did not work because the Judge system had not yet been established and required too much knowledge about the Judge Dredd comic from the audience. He also considered the result too surreal and extreme. From this script, Garland decided that the story needed to be more focused and grounded. He instead considered adapting some of the notable Judge Dredd storylines, including "Democracy" (1986) and "Origins" (2006). He decided to avoid these lengthy tales in favour of a shorter, day-in-the-life story about Dredd and his function as a cop in the dystopian environment of Mega-City One. When developing the Judge Dredd character, Garland tried to closely follow that of the comic-book character, who undergoes only small personality changes over a lengthy period of time. He said:
Sources: en.wikipedia.org
In 1989, he played the role of Glen in two episodes of the television show The New Lassie. At the beginning of his career, DiCaprio had difficulty finding an agent. When he finally found one, the agent suggested that he change his name to Lenny Williams to appeal to American audiences, which he refused to do. DiCaprio remained jobless for a year and a half, even despite 100 auditions. Following this frustrating lack of success, DiCaprio was about to give up acting but his father convinced him to persevere, and he continued to audition. After a talent agent (who knew a friend of his mother's) recommended him to casting directors, DiCaprio secured roles in about 20 commercials. By the early 1990s, DiCaprio began acting regularly on television, beginning with a role in the pilot of The Outsiders (1990) and one episode of the soap opera Santa Barbara (1990), in which he played an alcoholic teenager. Following this, DiCaprio was cast in Parenthood, a series based on the 1989 comedy film. To prepare for the role of Garry Buckman, a troubled teen, he analyzed Joaquin Phoenix's performance in the original film. His work that year earned him two nominations at the 12th Youth in Film Awards—Best Young Actor in a Daytime Series for Santa Barbara and Best Young Actor Starring in a New Television Series for Parenthood. Around this time, he was a contestant on the children's game show Fun House; on the show he performed several stunts, including catching the fish inside a small pool using only his teeth.
=== Americas === The Americas were more highly influenced by the Doctrine of Signatures than China, India, or Africa, most likely because of their colonial history with Europe. The majority of insect use in medicine is associated with Central America and parts of South America, rather than North America, and most of it is based on the medical techniques of indigenous peoples. Currently, insect medicine is practiced much more rarely than in China, India, or Africa, though it is still relatively common in rural areas with large indigenous populations. Some examples to follow: Chapulines, or grasshoppers, are commonly consumed as a toasted regional dish in some parts of Mexico, but they are also used medicinally. They are said to serve as diuretic to treat kidney diseases, to reduce swelling, and to relieve the pain of intestinal disorders when they are consumed. However, there are some risks associated with consuming chapulines, as they are known to harbor nematodes which may be transmitted to humans upon consumption. Much like the termites of Africa, ants were sometimes used as medicinal devices by the indigenous peoples of Central America. The soldier cast of the Army ant would be collected and used as living sutures by Mayans. This involved agitating an ant and holding its mandibles up to the wound edges; when it bit down, the thorax and abdomen were removed, leaving the head holding the wound together. The ant's salivary gland secretions were reputed to have antibiotic properties.
=== Controversy and plasticity === In spite of a burgeoning literature supporting TPCs as the NAADP-regulated channel, this was challenged in 2012/13 by reports that TPCs are, instead, Na+ channels regulated by the endo-lysosomal lipid, Phosphatidylinositol 3,5-bisphosphate, PI(3,5)P2 and also by metabolic state (via ATP and mTOR). This controversy ultimately evolved into a new model of how TPCs work. The challenge raised two different, but interrelated issues: (a) TPCs are insensitive to NAADP; (b) TPCs are Na+- (and not Ca2+-) permeable.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.